ChapterPDF Available

Neuropathic and phantom pain. Influencing pain

Current approaches in the treatment of
neuropathic and phantom limb pain
Zsuzsanna Helyes M.D., Ph.D., D.Sc., Bálint Botz M.D.
Pécs University, School of Medicine, Department of Pharmacology and Pharmacotherapy
Scientific reviewer: János Tajti M.D., Ph.D.
Szeged University, School of Medicine, Department of Neurology
English grammar reviewer: Ian O’Sullivan B.Sc.
1. Introduction, etiology, symptomatology
1.1 The definition of neuropathic pain, the classification of neuropathies
Pain is generally divided into three large subgroups: somatic, visceral, and
neuropathic forms. Somatic and visceral pain are usually the warning signs of a
potentially harmful external factor (e.g touching a hot object) or disease (e.g
angina pectoris). In order to develop these painfuls sensations, the excitation of the
sensory nerve endings (either in superficial or deeper tissues/organs) is necessary.
Therefore these forms of pain are mostly beneficial, as they help to save the
structural integrity of the body (e.g. by forcing someone to rest an injured limb).
Neuropathic pain on the other hand is a direct consequence of the damage of
the nervous system itself, which is according to our current knowledge
practically irreversible. Thus, this form of pain is ”useless”, because it serves no
purpose while seriously hindering the patients life quality.
The definition of neuropathic pain is according to the IASP (International
Association for the Study of Pain): Pain caused by a lesion or disease of the
somatosensory nervous system.
The two main aspects in the classification of neuropathic pain:
1. The anatomical localization of the lesion
2. The etiology of the damage
By these two considerations most of the patients can be subdivided into four broad
categories (Table 1.)
Table 1. The etiology/anatomy based classification of neuropathic pain syndromes,
and some common causing factors
Painful peripheral neuropathies
Phantom limb pain
Traumatic neuroma, nerve injury
Postherpetic neuralgia
Diabetic mononeuropathy
Ischaemic neuropathy
Lyme Borelliosis
Peripheral nerve tumours
Radiotherapy-induced neuropathy
Vascular and other nerve
Diabetic polineuropathy
Alcoholic neuropathy
Beri-Beri, Pellagra
Antiretroviral drugs
Cisplatin, paclitaxel, oxaliplatin
Amyloid neuropathy
Paraneoplastic neuropathy
(carcinomas mostly)
Lyme Borrelliosis
„Trench foot” (freeze injury)
Idiopathic neuropathies
Central pain syndromes
Vascular neuropathies
(haemorrhagic/ischaemic stroke)
Sclerosis multiplex
Traumatic injury of the brain or spinal
Complex pain forms of mixed
neuropathic and other origin
CRPS (Complex Regional Pain
Syndrome I,II)
Chronic low back pain with
1.2 The epidemiology of neuropathic pain
To determine the exact prevalance of neuropathic pain in the population is difficult,
especially in societies with generally low health awareness. According to current
estimations neuropathic pain can affect as much as 7-8% of the population in
Western-Europe. Most of them are left undiagnosed, but even many of those who are
get eventually „lost” in the health system, receiving improper/inadequate treament. A
significant percentage of patients does not reach a specialist, and still many try to cure
themselves by OTC (over the counter) drugs and other remedies (unsurprisingly -
without success).
The largest group of the patients affected by neuropathic pain are the middle-aged
and elderly. Women and people with low SES (socioeconomic status) are also
affected more often. The most common cause in developed countries is diabetes
mellitus. During the long course of this disease, significant amount of patients develop
the typical symptoms of diabetic polineuropathy, even when receiving adequate
therapy. Half of those who have suffered spinal cord damage, and 8% of those who
had a stroke develop neuropathic symptoms. 10-40% of patients with helpes zoster
have also neuropathic symptoms. 10-20 years after the first manifestation of sclerosis
multiplex, most of the patients develop chronic neuropathic pain. Among the other
common causes trigeminal neuralgia, malignant tumours (either direct invasion of the
neural system or the side effect of chemotherapy), operations (thoracotomy,
mastectomy, laminectomy) worth mentioning. A significant amount (30-40%) of
patients suffering from low back pain, also develop later neuropathic symptoms.
CRPS (Complex Regional Pain Sydrome I,II) should be noted as a special form of
neuropathy, which is mainly caused by minor injuries, and its pathophysiology is not
perfectly understood, but it is assumed that immune reactions have a key role in it
(According to the now obsolete terminology CRPS I. was called Reflex Sympathetic
Dystrophy, while CRPS II. was named Causalgia).
It must be emphasized that, the loss of life quality is the main adverse effect of
neuropathic pain during its long course (measured by e.g. QUALY=Quality Adjusted
Life Years, or DALY=Disability Adjusted Life Years). As a chronic, progressive
disease, most of the patients develop secondary comorbidities (the most common
being secondary depression, anxiety, insomnia etc.).
1.3 The symptoms of neuropathic pain
A damage to the nervous system has two potential consequences: 1. loss of the
somatosensory functions 2. abnormal (extra) perceptions. Therefore traditionally
the symptoms of neuropathies are categorized into negative (loss of function), and
positive (abnormal extra functioning) symptoms.
A negative symptom can be for example the loss of various sensory modalities
(tactile, sensory etc.), hypesthesia (decreased pain perception), loss of vibration
sensing. Though the patient experience these symptoms, and they indeed form an
obstacle in the everyday life, but they are all painless. Thus the patients sooner or
later habituate to the changed bodily perception (e.g. they switch to use their other,
more skillful hand).
The positive symptoms on the other hand are always disturbing. The patients
can not habituate the continous, uncomfortable, painful sensation, their life quality
deteriorates. During the long course of the disease most of them will at one point
or another develop the so-called „pain-personality”, which is practically a
secondary depression. The most common positive signs are paresthesia
(spontaneous, uncomfortable, but not clearly painful sensation), dysesthesia
(spontaneous, painful sensation, „pins and needles”, burning feeling),
hyperalgesia (decreased pain threshold), allodynia (painful sensation caused by
normally non-painful stimuli e.g. mild tactile, thermal).
Fig 1.: The types of neuropathic pain on the basis of their intensity and causing factor.
After: Cervero F, Laird JMA Mechanisms of touch-evoked pain (allodynia): a new model. Pain 1996
68: 13-23.
1.4 Special remarks on phantom limb pain
It is a long-standing clinical experience, that patients who have lost a limb due to
injury/operation often complain about a peculiar feeling as if the lost, „phantom” limb
would be still the part of their body. This sensation is varying widely among the
affected, it can be as simple, as the incorrect proprioception (sense of position), but it
can also manifest itself as severe pain, dysesthesia, numbness, prickle as well.
Phantom limb pain is defined as incorrect nociceptive stimuli arising from a no
longer existing extremity. This phenomen is affecting in varying degree, but
approximately two third of amputated patients, therefore it is a very common
complication after the loss of a limb. The pathopysiological basis of phantom limb
pain is similar to other neuropathies, with a few unique characteristics. In phantom
limb pain the primary lesion is the damage of the axons in the peripheral nervous
system, which is in turn further worsened by central maladaptive changes. It is an
interesting fact, that among those who suffered the loss of a limb at a younger age, the
incidence of phantom limb pain later on is much less common.
2. Pathogenesis
2.1 About the etiology of neuropathic pain in general
When classifying peripheral neuropathies, we generally differentiate mono- and
polineuropathies (whether one or several nerves are affected). The
mononeuropathies are mostly caused by injuries or compression. The latter one is
most commonly encountered in clinical settings as carpal tunnel syndrome. The
polineuropathies have mostly metabolic (e.g. diabetes) or toxic (e.g.
chemotherapy) origin. The immune-mediated neuropathies are far less common,
even their most common form, the Guillain-Barré-syndrome has only an incidence
around 1-2/100 000/year.
There can be three distinct pathophysiologic processes in the background of
peripheral nerve damage. One of them is the so-called Wallerian degeneration, in
which case the neural (axon, myelin) and other (epi, peri, endoneurium) parts of
the nerve are damaged simultaneously (a.k.a. neuronopathy). This is mostly caused
by physical injury. In this case, the complete healing is unlikely. Spontaneous
recovery is incomplete mostly, usually caused by collateral neurotransmission by
an other nerve fiber (axonal sprouting). Sadly, this mechanism is not only
inefficient, but by establishing incorrect connections between axons carrying
different modalities, it becomes also a key source of painful symptoms (like
Normally the different sensory modalities are conveyed well-separated from
each other to the CNS
If the myelin sheath is damaged (myelinopathies), the axons will be no longer
isolated, and the action-potentials can abnormally propagate, which is the
source of pathologic painful sensations.
In case of the injury of a peripheral nerve (mostly due to acute trauma), the
healing is rarely adequate. Some of the distal axons will form incorrect
connection, whereas those that can not reconnect will eventually perish. In the
example above the conductance of painful and heat stimuli ceases, and the the
tactile decreases (negative symptoms). On the other hand the incorrect
connections make it possible to convey tactile and heat stimuli incorrectly as
painful signals (positive symptoms).
Fig 2.: The mechanism of the development of dysesthesias in peripheral
An other possible mechanism is primary demyelinisation (a.k.a.: myelinopathy).
In this case the lesion affects principally the myelin sheath, while the axons are
initially unaffected. The loss of the myelin leads to the impairment of saltatoric
neurotransmission, slower conductance of action potentials, in the most severe
cases: complete blockade.
Axonal neuropathy is the rarest form, but it is infamous for its devastating effect.
Its first step is the damage of the axons, but the underlying cause is currently only
partially understood (endogenous toxic substances, and the impairment of the
axonal flow are the assumed triggering factors). The three main mechanisms are
summarized on Fig 3.
Fig 3.: Types of peripheral nerve damage that lead to neuropathic pain
When considering the main symptoms, we can differentiate motor, sensory,
autonomic, and mixed neuropathies. The most notewothy forms are the sensory
neuropathies, as many endemic diseases (diabetes, alcoholism, malnutrition) lead
to this condition, which affects a significant part of the population. However the
other forms deserve attention as well. To underline this, we would like to mention
as an example, that the neuropathy of the autonomic nervous system in diabetic
patients at least doubles their cardiovascular mortality.
The diagnostic approaches of neuropathies are well elaborated, taking the history,
performing the physical examination, and some special diagnostic measurements
(electromyography-EMG, electroneurography-ENG) usually leads to the
diagnosis. For monitoring the progress, and to assess the severity of the disease,
several questionnaires are available. The most widely used is the DN4
questionnaire (Douleur Neuropathique en 4 Questions). By asking two simple
questions and performing two short physical examination, even a general
practitioner can decide whether the patient suffers from somatic or neuropathic
pain (Table 2.).
We need to emphasize though, that even these days, the underlying disease can not
be elucidated in 20-30% of the patients (idiopathic forms origin currently
Overview of the DN4 questionnaire
Question 1.: Does the
pain have one or more of
the following
1. Burning
2. Painful cold
3. Electric shocks
Pain caused by cold/hot
stimuli normally below
the pain threshold, are
characteristic to
Question 2.: Is the pain
associated with one or
more of the following
symptoms in the same
5. Pins and needles
6. Numbness
7. Itching
Tingling and numbness
are typical negative
symptoms of neuropathy,
and are rarely caused by
somatic pain. Pins and
needles pain is common
in peripheral
Examination 1: Is the
pain located in an area
where the physical
may reveal one or more
of the following
8. Hypoesthesia to touch
9. Hypoesthesia to
The presence of negative
symptoms in a
dermatoma where the
patient localises pain is a
characteristic feature in
Examination 2: In the
painful area, can the pain
be caused or increased
10. Brushing
This examination can
reveal allodynia.
Assesment: During the test each „yes” answer means 1 point, the maximum is 10
points. 4 or more points suggest that the patient suffers from neuropathic pain.
3. Pathomechanisms
During the development of neuropathic pain, irrespectively of the original disease and
the localisation of the primordial injury, secondary maladaptive changes occur at all
levels of the nervous system. A main consequence of this for the practicing physician
is, that these processes lead sooner or later to constant pain and resistance to
analgesics. Therefore, we describe the key mechanism beginning from the periphery
and proceeding towards the central nervous system (CNS).
Fig 4.: Schematic representation of the key mechanisms involved in the
development of neuropathic pain, and their place in the process.
3.1. The sensitization of sensory nerve endings (peripheral sensitization)
The sensory nerve endings (nociceptors) are either non-myelinised C or thinly
myelinised Aδ fibers. They can be specific to a distinct sensory modality (mechanical,
chemical, thermal stimuli), or polimodal. The nociceptors can be activated by both
external noxa and endogenous substances (inflammatory mediators, neurotransmitters,
growth factors, etc.).
After the axons of a peripheral nerve are damaged, begins the process called
Wallerian degeneration (mentioned earlier). Then, distal from the lesion both the
axon and the myelin sheath degrades, the necrotic tissue is infiltrated by macrophages
and T-cells causing a sterile inflammation. The released inflammatory mediators and
growth factors locally decrease the nociceptive threshold leading to hyperalgesia a
key symptom of neuropathies. This mechanism seems to be especially important in the
development of CRPS I. and postherpetic neuralgia.
One of the most prominant pathways involved in the development of sensitization are
the members of the Transient Receptor Potential (TRP) receptor family, which are
situated on the nociceptors, andare activated in this process. The role of the TRPV1
receptor worths mentioning in particular. This receptor is activated by capsaicine
(which causes the pungent taste of red pepper), but its „normal” activators are painful
heat stimuli and several endogenous inflammatory mediators (lipoxygenase products,
acidic pH etc.). After all it is not surprising that their increased activation leads to a
distinct burning sensation in neuropathies. The role of the other receptors belonging to
the TRP family (TRPA1, TRPM8) have not yet been clearly elucidated.
3.2 The abnormal, ectopic excitation of the sensory nerve endings
The altered excitability and spontanous discharge of nerve fibers has a key role in
the development of the positive symptoms of neuropathy. On a cellular level this can
be explained by the increased expression of the voltage-gated sodium channels.
Therefore it is understandable, that drugs blocking the sodium channels
(carbamazepine, oxcarbazepine, phenytoine, lidocaine) are often found to be
beneficial in neuropathic patients. The tricyclic antidepressants (TCA) also have
sodium channel-blocking effect, thus they can be used effectively in the treatment of
neuropathic pain, whereas the selective serotonine reuptake inhibitors (SSRI), have no
such effect.
3.3 Pro-nociceptive (pain sensation-increasing) changes in the spinal dorsal root
(central sensitization)
The central endings of the pseudounipolar primary sensory neurons form synapses
with the secondary sensory neurons in the spinal dorsal root. The main excitatory
neurotransmitter of the central nervous system (and therefore also in the nociceptive
system) is the glutamate, which has three known receptors (AMPA which is linked
to ion channel, the NMDA [N-metil D-aspartate] receptors, and the Gs/q proteine-
linked metabotropic mGluR receptor). In the dorsal root the increased activation of
the AMPA receptors, and the release of NMDA receptors from the physiologic
blockade collectively leads to the increased excitability of the secondary sensory
neurons. This in turn makes them excitable by not only the C and Aδ fibers, but also
by the fibers. This can result in continous pain sensation (pin-prick hyperalgesia),
or pain evoked by normally non-painful stimuli (allodynia). Therefore it seemed to be
a logical step to block the glutamate-receptors, but the clinical studies addressing this
question ended with unconvincing results (memantine, dextrometorphan). Ketamine
on the other hand was found to be effective in the treatment of several neuropathic
pain syndromes.
3.4 The blockade of the spinal inhibitory system
The importance of the spinal inhibitory system was first highlighted by the so-called
thermal grid-illusion experiment (1896). In this easily reproducable experiment
warm and cold metal rods were placed next to each other in alternating pattern. If the
experimenter touches only one rod at a time, he/she can feel the hot/cold stimulus,
which is not uncomfortable (40/20 oC). However by touching more rods
simultaneously, the experimenter will experience painful burning sensation. The cause
of this phenomen is that the fibers conveying the warm stimuli block in the dorsal root
the Aδ fibers conducting the cold stimuli. This in turn causes that the C fibers
conducting painful heat stimuli are released from the physiologic blockade, and
wrongly they will conduct painful heat stimuli to the central complexes. This
phenomen is of great importance in the development of neuropathic burning pain.
An other important mechanism is the decreased functioning of the descending
inhibitory pathway of the nociceptory system (the role of the endomorphins is
particularly emphasized). In the meantime, the cholecystokinine-receptor expression
increases in the dorsal root (cholecystokinine antagonizes the effect of the
endomorphins and exogenous morphin as well). The therapeutic effect of several
drugs can be explained by the enhancement of this inhibitory mechanism (SNRI-s,
SSRI-s, TCA-s, duloxetine, venlafaxine, valproate etc.) Among the non-
pharmaceutical treatments the Transcutaneous Electric Nerve Stimulation (TENS),
and the Spinal Cord Stimulation (SCS) also affects this inhibitory pathway.
3.5 Pain maintained by sympathetic activation
In case of sympathetically maintained pain, abnormal connections are formed
between the sympathetic and sensory systems, which are physiologically well-
separated. Several studies have verified, that in neuropathic pain models the
sympathetic afferents exert an inhibitory effect on nociceptive afferents in the spinal
dorsal horn. This mechanism has a pivotal role in the development of complex
regional pain syndrome, phantom limb pain, and traumatic neuropathies.
3.6 Central reorganization
The significance of the alterations that occur primarily or secondarily in the central
nervous system was for a long time unexplained. The modern functional imaging
techniques (MRI tractography, Diffusion tensor technique, PET etc.) made a huge
impact on this field. It is certain, that every pain syndrome that becomes chronic
(which is characteristic of neuropathies) induces secondary changes in the CNS.
However, in particular neuropathic pain syndromes (e.g. post-stroke neuropathy) the
CNS lesion is the primary trigger. The neuronal rearrangement that occurs in the
cortex is rarely beneficial. The defined somatotopic (correspondence of an area of the
body to a specific point of the cortex) pattern can be altered. This is especially
marked in phantom limb pain, in which case this leads to a more intensive pain
sensation. Besides the cortex, the deeper cerebral structures can also be affected,
e.g. the periaqueductal gray matter (PAG), and the rostral ventral medulla (RVM).
Nevertheless whether these changes are definitely pro- or antinociceptive is still a
matter of debate. Unfortunately none of the currently available medications target this
mechanism, but there are some potential therapeutic methods in the early clinical
research (e.g. transcranial magnetic stimulation) that seem to have a beneficial effect
in these conditions.
3.7 The characteristics of the development of phantom limb pain
Traditionally the development of phantom limb pain was mainly attributed to the
ectopic stimuli arising from the peripheral (stump) neuroma. In this case the on the
end of the injured nerve the fibers become demyelinised, and abnormal connections
are formed between them (ephactic crosstalk). The spontaneous excitability of the
fibers also increases.
The early clinical evidences showed, that local anesthesia rarely gives relief to the
patients. This raised the idea, that in the development of phantom limb pain
reorganization processes in the central nervous system might be also involved. On
spinal level the dorsal root ganglion (DRG) plays the key role, as this is the source of
ectopic stimuli, and pathologic interactions between the sympathetic and sensory
nervous systems. This explains also the fact, that the symptoms of phantom limb pain
are worsened during emotional stress. The long-lasting abnormal stimuli arising from
the periphery will sooner or later lead to permanent changes in the responsiveness or
the DRG neurons: resulting in the development of central senzitization. An other
important change is the down-regulation of the opioid receptors, the decrease of
GABAergic neurotransmission, and the increased expression of Substance P (SP).
The supraspinal changes form the last part of this process. After their development the
phantom limb pain becomes chronic, its curability decreases. The dislocation of the
representational areas of the primary somatosensor and motor cortex is characteristic,
as well as the reorganization processes in the thalamus.
It is an interesting fact that in several cases the character of phantom limb pain is akin
to the somatic pain felt there before the loss of the limb. This gave researchers the
idea, that these so-called „pain memories” can be important factors in the development
of phantom limb pain. Clinical studies have also verified that the best prognostic
factor of phantom limb pain after amputation is chronic pain felt in the affected limb,
before its loss (though we have to mention that patients, who have lost their limb due
to acute injury were not enlisted in this study).
4. Pharmacotherapeutic management of neuropathic pain
When discussing the pharmacotherapy of neuropathies, it is important to note that non-
steroid anti inflammatory-analgesic drugs (NSAID) which are the most popular and
widely used OTC painkillers, are largely ineffective in neuropathic pain syndromes.
However their several side-effects can result in severe complications (which is often
encountered in patients who try to cure themselves). At the same time the formerly widely
used term of „morphine-resistant pain” is unsubstantiated and incorrect, therefore it
should be avoided in the future. The main challenge is that the currently available
therapeutic options are symptomatic at best. Moreover even our most up to date drugs
like duloxetine and pregabaline give significant relief only in one patient out of four,
and even in their case they only give approximately 50% pain relief.
4.1 Drug groups used in the treatment of neuropathic pain
4.1.1 Drugs used in the first line
The tricyclic antidepressants (amytriptyline, nortryptyline, imipramine,
desipramine) mediate their effect mainly by the central inhibition of the
monoamine reuptake. Unfortunately, their clinical use is limited by their numerous
and severe side-effects. Their effect is the increase of the concentration of
monoamines (noradrenaline, dopamine, serotonine) in the synaptic cleft. Therefore
the monamines effect is facilitated in the descending pain-inhibitory pathway.
Several clinical studied provided evidence of their effectiveness in HIV-associated
and chemotherapy-induced neuropathies. Their antidepressant effect is also
beneficial, as the mood disorders are the most common comorbidity of chronic
pain syndromes. Their relatively low price is also an advantage (practically all of
them are available as generic drugs), as well as their convenient dosage (1x1
daily). Unfortunately their side-effects, especially on the cardiovascular system,
and their muscarinic receptor agonism (dry mouth, orthostatic hypotension,
obstipation, urinary retention) make them also dangerous and hard to tolerate.
Their cardiotoxic effect must be also taken into account, as they can only be used
in lower doses and with regular ECG controls in patients with ischemic heart
disease (N.B. diabetes-IHB is connected!) or ventricular conductive abnormalities.
Venlafaxine and duloxetine act through similar mechanism, but they selectively
block the reuptake of noradrenaline and serotonine (selective serotonine-
noradrenaline reuptake inhibitors-SSNRI). They were found to be particularly
beneficial in diabetic neuropathies. Regarding their side-effects duloxetine was
found to be safe, as it has no adverse cardiac effects, though it rarely causes
nausea, whic can be avoided by gradual increase of the dose at the beginning of
the therapy. Venlafaxine on the other hand can lead to conductance abnormalities
and elevated blood pressure, therefore the dose must be carefully adjusted at the
beginning and the end of therapy,
Gabapentine and pregabaline were originally marketed as antiepileptics, but
today they are one of the most favoured and prescribed drugs in neuropathies as
well. They are safe, largely free from untoward side-effects. Currently they form
the first step in the pharmaceutical treatment of most neuropathic pain syndromes
in developed countries. Despite the fact that they were developed to be GABA
analogues, in neuropathies the inhibition of voltage-gated calcium-channels is their
main effect. This in turn leads to the blockade of neurotransmitter-release. As both
drugs are well-tolerated and have no dangerous interactions they are especially
advantageous for elderly, comorbid patients. However both can cause vertigo or
sedation in the beginning, which can be mostly avoided by the slow titration of
therapeutic dosage. In patients with severe impairment of renal functions,
increased caution, if necessary dose reduction is required (the creatinine-clearance
is used to determine this). The bioavailability of creatinine surpasses that of the
gabapentine, thus a faster onset of effect can be expected (as gabapentine has
nonlinear pharmacokinetics, the therapeutic dose can be reached only slowly and
stepwise, pregabaline has linear pharmacokinetics which makes its dosage easier).
Lidocaine is a well known anesthetic, but it is also useful in neuropathies (it
blocks the voltage-gated sodium channels mentioned earlier). Unfortunately its
low plasma half-life limits its applicability. Therefore it is mainly applied
topically, with sometimes surprisingly long-lasting analgesic effect. The 5%
lidocaine patch was found to be effective and well tolerated in postherpetic
neuralgia, and a variety of neuropathic allodynias. Because this way only a small
amount of it is absorbed, it is largely free from systematic side-effects. The 5%
lidocaine gel is also effective, but is much cheaper than the patch. On the whole
we can expect relief from topical lidocaine in peripheral neuropathies, but is
absolutely ineffective in centrally maintained pain syndromes.
4.1.2 Drugs used in the second line (in some cases they can be in the first line)
Tramadol mediates its analgesic effect through a dual mechanism: as a μ-opioide
receptor agonist it blocks the ascending nociceptive pathways, and it also activates
the descending monoaminergic inhibitory system (noradrenaline and serotonine
reuptake inhibition). The analgesic effect is potentiated by these two mechanisms.
It can be used effectively in postherpetic neuralgia, diabetic polineuropathy, an
almost all painful polineuropathies. It is weaker analgesic when compared to the
„classical” opioids (morphine, oxycodone etc.), but its effect has similarly fast
onset, and the risk of addiction is much lower. Its side-effects are similar to the
other opioids, it can cause seizures and when combined with SSRI or SSNRI drugs
can produce life-threatening serotonine-syndrome.
Tapentadol is a novel opioid agonist with similar mode of action. It was found to
be effective in the management of diabetic polineuropathy. As it is a relatively
new, original drug, its cost is higher.
The debate about the role of the other opioid drugs in the therapy of neuropathies
is far from settled. In a comparative study, in which patients with postherpetic
neuralgia were sequentially treated with opioid, tricyclic antidepressant, and
placebo, the patients unambigously preferred the opioid. Among their several side
effects, the obstipation, nausea, and sedation must be emphasized. During the
chronic treatment, dependance occurs also almost unescapably (therefore at the
end of therapy the dose must be reduced gradually).
Considering these limitations, opioid painkillers are today usually advised only if
the analgesic effect of first-line drugs is no longer sufficient. There are however
some exceptions, when opioids can already be used in the first line of treatment
(usually tramadol). Some examples are acute neuropathy, neuropathy caused by
malignancy, acute exacerbation of chronic neuropathy, and transitionally until the
onset of the effect of first-line drugs. Special care must be taken in case of patients
who are susceptible of drug-abuse, patients with chronic airway diseases. Opioids
with effect lasting longer (sustained release preparations) are squarely
4.1.3 Third line drugs (drugs used mostly in some distinct neuropathic entities)
Carbamazepine is an antiepileptic drug, which has strong sodium and less potent
calcium channel-blocking ability. It is relatively popular in the outpatient
treatment, and is a first line drug in trigeminal neuralgia. It is also beneficial in
some other froms of neuropathy, like postherpetic neuralgia and herpes zoster.
Lamotrigine is part of the second-line treatment in post-stroke neuropathy,
whereas there is less evidence about the value of valproate, topiramate, and other
anticonvulsants. The recent results show that they might be useful in the
management of diabetic, HIV-induced, and post-stroke neuropathy.
NMDA-receptor anatgonists seem to mediate they effect through the inhibition
of central sensitization. Ketamine is efficient in the treatment of postherpetic
neuralgia, whereas the orally administrated NMDA antagonists
(dextrometorphane, memantine etc.) were found to be useful in diabetic
The potential of selective serotonine reuptake inhibitor (SSRI) drugs is not
evident. In the clinical studies paroxetine and citalopram were found to be
moderately beneficial, while fluoxetine proved to be ineffective when compared to
4.2 The management of neuropathies caused by lesions of the central nervous
Far less clinical data are available about the management of the neuropathies, that are
caused by a primary lesion in the central nervous system, or in which the pain is
maintained by mostly central mechanisms (though as we have seen earlier, all CNS
changes are at least partially involved in all neuropathies).
According to recent evidence, in post-stroke neuropathy the TCA, SNRI, and Ca2+-
channel blocker drugs are useful. In neuropathy related to spinal cord injuries, the
Ca2+-channel blockers and tramadol were found to be effective. The endocannabinoid
system is also a promising target in sclerosis-multiplex-associated neuropathies (see
4.3 About the therapy of phantom limb pain
The general observations about the treatment of neuropathies are especially true t
phantom limb pain: the effectiveness of the therapy is insufficient, regarding both the
pharmaceutical and other (e.g. nerve stimulation) treatments. The expected result is
modest at best, and few and mostly non-controlled clinical study data are available
about the management of these conditions. The analgesic effect seldom surpasses 30%
(measured by e.g. visual analogue scale).
The opioids, ketamine, dextrometorphane and gabapentine were found to have
significant analgesic effect. There are less available data about the usefulness of the
topical lidocaine therapy.
5. EBM (Evidence Based Medicine) data
5.1 Clinical studies in neuropathic pain
It is important to note that we only have verified data about a minority of
neuropathic conditions. The randomized, controlled trials (RCT) performed so far,
mainly focused on either postherpetic neuralgia, or painful diabetic
polineuropathy. It is also disadvantageous, that there are hardly any cross-over
studies, in which different drugs/preparations would be self-controlledy compared
to each other.
It is therefore essential to be critical about or current knowledge of therapeutic
modalities, as much of that will certainly have to undergo revision in the future. A
good example of this is HIV-associated neuropathy, which is surprisingly resistant
to first-line drugs. Chemotherapy-induced neuropathy, and lumbosacral
radiculopathy are also resistant to analgesics.
We have to emphasize, that in the management of neuropathies, only the
mechanism-centered approach could lead to success, and when choosing the
adequate therapeutic modalities, individual treatment, tailored to the patients
disease and symptoms is necessary.
5.2 Monotherapy vs. combinations
It is a long-standing tradition in medicine, that the pharmacotherapy of a patient
must be kept as simple as possible, as otherwise the compliance would decrease
dramatically. Therefore it is an understandable intention to keep the patient at
monotherapy, and employ the simplest, most easily remembered administration
protocol (e.g 1x1 daily). Unfortunately as we have seen earlier, the development of
the neuropathic pain is a complex process, which automatically means that we
have a lot of targets as well. Aiming for only one target at a time rarely provides
acceptable life quality for the patient.
The proper approach therefore is to start with monotherapy, but if the analgesic
effectproves to be insufficient, we have to switch early to the combination therapy
with a drug acting on a different target (but always carefully considering the
possibility of interactions!).
Unfortunately there is only a limited evidence concerning the best drug
combinations. According to recent studies gabapentine + sustained-release opioids,
or TCA + gabapentine combinations make it possible to decrease the dose of both
drugs, though clear and concise guidelines are badly lacking. Pregabaline can be
succesfully combined with gabapentine, TCA, and tramadol. The 8% capsaicin
patch (see later), can be combined with almost anything (if there are no
5.3 Clinical recommendations about the drugs currently on the market
Table 4. Drugs used in the most important neuropathic pain syndromes, grouped
by their reccomendation level
First line
Second line
Diabetic neuropathy
venlafaxin ER
Postherpetic neuralgia
Lidocaine patch
capsaicine patch
Trigeminal neuralgia
treatment (surgical
Central pain syndromes
Neuropathies caused by
Phantom limb pain
Note: According to the 2010 guideline of EFNS (European Federation of
Neurological Societies)
If we can no longer guarantee acceptable life quality by pharmacotherapy, in
certain neuropathic diseases other, non-pharmacotheraoeutic options (mostly nerve
stimulation) can be started (for details see Table 5.).
Table 5. Recommendations about the application of non-pharmaceutical treatments
in the analgesic-resistant neuropathic conditions
Spinal cord injury, post-stroke pain
Stimulation of the motor cortex by
transcranial magnetic stimulation
Phantom limb pain
Deep brain stimulation of the thalamus
and PAG
CRPS, pain arising after surgery of
the spinal column („failed back
Epidural stimulation of the spinal dorsal
cord (SCS)
Facial pain, post-stroke pain
Stimulation of the motor cortex (MCS)
Source: Cruccu et al. EFNS guidelines on neurostimulation therapy for neuropathic
pain. Eur J Neur 2007;14:952-70
5.4 Practical remarks on the therapy
According to the clinical experience, if the pain is neuralgic (shock-like) then the
best results can be expected from carbamazepine. If for some reason the patient
does not tolerate it, then oxcarbazepine, gabapentine, pregabaline, sometimes
lamotrigine are used.
In chronic, non-neuralgic pain the TCA drugs are recommended, but if they are
not tolerated, then duloxetine, venlafaxine, gabapentine, or pregabaline are also
useful. The Quatenza capsaicine-patch can also be used in non-diabetic
peripheral neuropathies.
Until the onset of sufficient analgesic effect, the temporary use of mild sedatives,
benzodiazepines is also accepted to relieve the patient from the accompanying
sleeping disorder and stress.
As we have mentioned earlier, the complete absence of pain is a rarely achieveable
goal in chronic neuropathies. Thus, it is useful to make a therapeutic agreement
with the patient. For example: if we determine the actual pain of the patient before
the beginning of the therapy by Visual Analogue Scale (0-complete absence of
pain, 10-unbearable pain), we can mark a target value (which should never be zero
in the first step).
It is important to detect early those patients, that can longer expect acceptable life
quality from pharmacotherapy. In their case functional neurosurgical interventions
can help.
5.5 About the effectiveness of treatment
When comparing the effect of different drugs, one of the most important indicator is
the Number Needed to Treat (NNT). NNT shows us how many patients we have to
treat lege artis with a given medicine, to reach definitive improvement in one of them
(that means in our case less intensive pain). Traditionally in analgesic research
„definitive improvement” is described as at least 50% decrease of pain sensation.
According to clinical experience, NNT value is around 3 in neuropathies even in case
of the most potent analgesics (TCA, sodium channel-blockers, opioids) (Fig. 5) that
means that we can only expect significant improvement in one subject out of three
properly treated(!) patients! Therefore it is understandable, how limited our current
therapeutic modalities are. It is especially true if we mention that even among patients
who react to therapy, the effect is nearly always partial.
Fig. 5: Number Needed to Treat (NNT) of some of the most commonly used systemic drugs
in neuropathies.
Based on: Finnerup et al. Algorithm for neuropathic pain treatment: an evidence based proposal
Pain 2005 118: 289-305.]
6. Potential new therapeutic modalities (clinical and preclinical data)
The modest results of pharmacotherapy in the management of neuropathic pain can be
explained by the fact, that nearly all drugs currently on the market were discovered by
the serendipity method (literally: „happy accident”), sometimes only after the drug has
already entered the market with different indications (e.g pregabaline was originally
developed as an antiepileptic, while TCAs as antidepressants).
It is very hard to determine in neuropathic conditions, that even if a drug passes the
preclinical phase (which also has many pitfalls due to the difficulties of animal
experiments), that what kind of patients should we involve in the clinical trial. An
other problem is, that what can we measure at all, what kind of indicators can help us
to determine the presence/lack of effect. Nowadays, mostly patients with postherpetic
neuralgia or diabetic polineuropathy are chosen for the Phase II,III trials, as these are
the most common neuropathic disorders.
The better understanding of the cellular and receptorial pathways responsible for the
transmission of pain made in the last two decades possible, to start the development of
specific drugs against the most important mechanisms/target molecules (Table 5.)
Table 6. Novel targets (drugs, mechanisms currently in clinical/preclinical research)
Glutamergic receptors
Phase I, II clinical trials with agonists
acting on Metabotropic, AMPA, or
NMDA receptors
TRPV1 receptor
Phase I, II, III studies with different
antagonists, and with some agonists that
permanently activate the receptor and
desensitize the nerve ending. The recently
approved Qutenza dermal patch contains
8% capsaicine. By opening the TRPV1
ion channel, the large Ca2+ influx causes
permanent desensitization of the nerve
ending. The patch can be applied to the
painful area after local anesthesia, and it
still requires cautiousness. Its effect is
long-lasting (approximately 12 weeks
after a 0,5-1 h treatment session). Based
on evidence gained so far it is beneficial
in a wide variety of peripheral
neuropathies (postherpetic neuralgia,
AIDS). It is contraindicated in diabetic
neuropathies, as it presumably decreases
skin microcirculation, thereby promoting
CBr1 cannabinoid receptor
Phase I, II studies with agonists in central
pain syndromes and sclerosis multiplex
Voltage gated potassium and sodium-
Retigabine (Trobalt/Potiga, Valeant
Pharmaceuticals) is an agonist on the
KCNQ voltage gated potassium channels.
It was approved in 2011. Its main
indication is currently the treatment of
partial epilepsies, but it holds out a
promise to be a useful tool int he
management of neuropathies and
migraine as well.
Lacosamide (Vimpat, UCB) is a novel
antiepileptic drug, which acts on the
voltage-gated sodium channels. The
results obtained so far were unconvincing
regarding its effect, in phase I, and II.
studies only marginal difference was
found when compared to placebo.
Ralfinamide (Newron Pharmacuticals) is
a dual-action voltage gated sodium
channel blocker/MAO-inhibitor. The
preclinical experiments were so far
convincing, but in the clinical phase
(SERENA trial) they could not find any
remarkable effect in patients with
neuropathic-radiculopathic pain.
Botulinum toxin
The potential of intradermal application
of botulinum toxin can not yet be decided.
In some studies it was found to be
effective in the treatment of neuropathic
mechanical allodynia, whilst other trials
did not manage to verify this.
Gene therapy, other possibilities
All of these developments are currently in
the preclinical phase, their apperance in
clinical practice can only be expected on
Among the ideas so far raised, the
intrathecal/intraspinal introduction of the
genes of endogenous analgetic peptides
(endorphines, enkephalines) with viral
vectors can be a promising tool. The
direct introduction of the glutamated-
decarboxylase gene near the peripheral
nerves was also suggested.
Simple choice
1. Which statement is true?
A In the development of neuropathic pain the damage of the peripheral nervous
system is always involved.
B The prevalence of neuropathic pain in the european population can be as high
as 7-8%.
C It is advised to begin the treatment of neuropathic pain with NSAIDs (Non-
Steroide Antiinflammatory Drugs).
D Opioids are ineffective in neuropathies, therefore they are not advised.
E In most neuropathic patients, monotherapy alone guarantees complete absence
of pain.
Explanation: The correct answer is B, as the prevalence of neuropathic patients in
the european population as around 7-8% according to current estimations.
Answer A is incorrect, as neuropathies can arise also as a consequence of purely
central lesions (e.g. post-stroke neuropathy). The NSAIDs are ineffective in
neuropathies, and should be avoided. Opioids on the other hand are useful, if
applied in correct dose and well-indicated. Total absence of pain is rarely possible
in neuropathies, especially not with monotherapy.
2. Whic statement is false?
A Peripheral senzitization is also involved int he development of hyperalgesia.
B TRPV1 receptor can be activated by noxious heat stimuli.
C Alterations of the CNS are rare in neuropathies, and can easily be treated with
D Glutamate is an important excitatory neurotransmitter of of the nociceptive
Explanation: As neuropathic pain is usually long lasting, secondary maladaptive
changes of the CNS develop very often, which are surprisingly resistant to therapy.
3. A patient comes to you, whose main complain is a severe pain (Visual Analogue
Scale: 9), which after taking the DN4 questionnaire appears to be neuropathic. The
patient has been taking NSAIDs for two months for relief without success. What
do you do in this situation?
A Increase the dose of NSAID, ask for neurosurgical expert opinion.
B Forbid NSAIDs, prescribe opioide instead.
C Leaves the dose of the NSAID unchanged, supplements the treatment with
carbamazepine and tramadol, directs the patient to psychiatry due to presumed
D Directs the patient to neurology, forbids further NSAID self-medication.
Explanation: NSAID treatment in this case is obviously useless, but its side-effects
(e.g. gastrointestinal erosions) can even further worsen the patients condition. In
the management of neuropathic pain we have to seek after an early diagnosis of
the etiology, as the causing factor can easily be an underlying severe disease (e.g.
malignancies), which calls for neurology specialist. As long as the etiology is
unclear, only careful pharmacotherapy is allowed (certainly noth with opioid
7. Which one of the following drugs should be given in the first line to patients with
trigeminus neuralgia?
A Tramadol
B Gabapentine
C Capsaicine-patch
D Carbamazepine
E Lamotrigine
Explanation: In trigeminus neuralgia carbamazepine is the first option.
8. Which one can be only carefully used in the treatment of patients with narrowed renal
A Carbamazepine
B Lidocaine patch
C Gabapentine
D Tramadol
E Duloxetine
Explanation: As gabapentine has a non-linear pharmakokinetics, it can easily
accumulate in patients with damaged renal functions.
Relation analysis:
A true-true, interrelated
B true-true, not interrelated
C true-false
D- false-true
E false-false
9. Allodynia belongs to the positive symptoms of neuropathic pain, as in allodynia
physiologically non-painful stimuli lead to painful sensation.
(true-true, interrelated - A)
Explanation: Allodynia is a typical „extra sensation”, therefore a positive
symptom, which is characterized by the pain sensation caused by normally non-
painful (e.g. tactile) stimuli.
10. Axonopathies have better recovery rate than myelinopathies, as in myelinopathies
pathologic pathways are formed between the different axons.
(false-true - D)
Explanation: Primary axonal damage has a very low spontaneous recovery rate. In
myelinopathies the axons lose their „insulation”, so action potentials can abnormally
11. The DN4 questionnaire helps the division of neuropathic and somatic pain, as NSAIDs
are always effective in somatic pain.
(true-false - C)
Explanation: With the DN4 questionnaire the caharcter of the pain can be described
by a few simple questions and physical examinations. NSAIDs are of course not
always effective, even in somatic pain syndromes.
12. In the management of neuropathies the early combination therapy is effective, as the
with the presently available drugs complete absence of pain can be achieved.
(false-false -E)
Explanation: In neuropathic pain the treatment is usually started with monotherapy. If
the analgesic effect later proves to be inefficient, we step further to combination
therapy. Complete absence of pain is rarely possible with the currently available
13. The mood stabilizing effect of tricyclic antidepressants is beneficial in neuropathic
patients, as they are hardly tolerated due to their relatively common side-effects.
(true-true, not interrealated - B)
Explanation: The mood stabilizing effect of TCAs is useful, as in patients suffering
from chronic pain secondary depression is common. Irrespectively of this fact, their
severe and frequently encountered side-effects limit their use.
Multiple choice questions
A 1,2,3 is true
B 1,3 is true
C 2,4 is true
D only 4. is true
E All answers are true
14. Which ones are positive symptoms from the following?
1. Allodynia
2. Paresthesia
3. Hyperalgesia
4. Hypesthesia
(1,2,3 - A)
Explanation: Hypesthesia means diminished pain sensation in an affected area,
therefore it belongs to the negative symptoms.
15. Which drug combinations are advantageous in the treatment of neuropathies?
1. Tricyclic antidepressant + gabapentine
2. Tramadol + tapentadol
3. Pregabaline + tramadol
4. Tramadol + SSRI
(1,3 - B)
Explanation: Tramadol and tapentadol are both weak opioids, therefore their combination
would not lead to additional benefit. Tramadol can cause dangerous serotonine-sydrome
when combined with SSRIs, therefore this combination must definitely be avoided.
16. In which is case is the utmost carefulness requiered in the use of tricyclic
1. Neuropathy caused by AIDS
2. If the patients has atrial fibrillation, and ventricular extrasystoles are present on the
3. If according to the medical history, the patient received medical treatment due to
depression earlier.
4. If the patient whose hypertension is long time known, show positive results on oral
glucose tolerance test.
(2,4 - C)
Explanation: The use of TCAs is especially risky if the patient has ventricular
conductance abnormalities. Long standing hypertension and impaired glucose
tolerance suggests metabolic syndrome and IHD, in which case TCAs could be
dangerous due to their cardiotoxicity.
17. In which case would you NOT apply capsaicine dermal patch?
1. Diabetic polineuropathy
2. Postherpetic neuralgia
3. Post-stroke depression
4. Posttraumatic mononeuropathy
(1,3 - B)
Explanation: Capsaicin can decrease the microcirculation of the skin in diabetic patients,
thereby promoting the formation of ulcers. Post-stroke depression is caused by purely the
lesion of the central nervous system, thus the topical application of capsaicine would be
A 1. is bigger than 2.
B 2. is bigger than 1.
C equal
18. In which case exists a higher risk of developing phantom limb pain?
1. Amputation of a limb due to sudden injury in childhood
2. Surgical amputation of the same limb due to chronic, painful disease (e.g. Buerger-
disease) in old age.
Explanation: If the amputation of the limb is preceeded by long-lasting somatic pain in the
same region, then the probability of later developing phantom limb pain is much higher
(„pain memories”). It is less proved, but phantom limb pain was found to be less commmon if
the amputation took place in the childhood.
19. Which neuropathic disease is more common?
1. Carpal tunnel-syndrome
2. Guillain-Barré-syndrome
Explanation: Carpal tunnel-syndrome is common, with a marked female dominance. The
immune-mediated Guillain-Barré-syndrome is a rare but life-threatening condition, requiring
early diagnosis and immediate medical attention.
Afilalo M, Morlion B Efficacy of Tapentadol ER for managing moderate to severe chronic
pain Pain Physician 2013;16:27-40.
Anand P, Bley K Topical capsaicin for pain management: therapeutic potential and
mechanisms of action of the new high-concentration capsaicin 8% patch British Journal of
Anaesthesia 2011;107:490502
Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of
neuropathic pain: 2010 revision European Journal of Neurology 2010;17:1113-23.
Backonja M, Woolf CJ. Future directions in neuropathic pain therapy: Closing the
translational loop The Oncologist 2010;15:24-29
Basbaum AI, Bushnell C. Science of pain Elsevier, 2009
Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with
nervous or somatic lesions and development of a new neuropathic pain diagnostic
questionnaire (DN4) Pain 2005;114:29-36.
Brown S, Simpson DM, Moyle G, et al. NGX-4010, a capsaicin 8% patch, for the treatment of
painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III,
randomized, controlled trials. AIDS Res Ther. 2013 Jan 28;10:5. [Epub ahead of print]
Cruccu G, Aziz TZ, Garcia-Larrea L, et al. EFNS guidelines on neurostimulation therapy for
neuropathic pain. Eur J Neur 2007;14:952-70.
Dworkin HR et al. Recommendations for the Pharmacological management of neuropathic
pain: An overview and literature update Mayo Clin Proc. 2010;85:S3-S14.
Haanpaa M, Treede RD Capsaicin for neuropathic pain: Linking traditional medicine and
molecular biology Eur Neurol 2012;68:264-75.
Jensen TS, Baron R, Haanpaa M, et al. A new definition of neuropathic pain. Pain,
Rang HP, Dale MM, Ritter JM, et al. Rang and Dale’s Pharmacology Elsevier 2012;521-4.
Nickel FT, Seifert F, Lanz S, et al. Mechanisms of neuropathic pain Eur
Neuropsychopharmacol. 2011;22:81-91.
Komoly S Fájdalomcsillapítás neurológusszemmel Lege Artis Medicinae 2011;1:213.
[Article in hungarian]
Komoly S - Palkovits M. Gyakorlati neurológia és neuroanatómia Medicina, Bp. 2010 [In
Tajti J, Szok D, Vécsei L. Új adatok a neuropátiás fájdalom patomechanizmusához:
terápiás evidenciák. Neuropsychopharmacologia Hungarica 2013;15:1 [Article in hungarian-
In print]
Zhang SH, Blech-Hermoni Y, Faravelli L, et al.. Ralfinamide administered orally before
hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous
neuropathic pain-related behavior in the rat. Pain. 2008;139:293-305.
ResearchGate has not been able to resolve any citations for this publication.
Full-text available
HIV-associated distal sensory polyneuropathy (HIV-DSP) is the most frequently reported neurologic complication associated with HIV infection. NGX-4010 is a capsaicin 8% dermal patch with demonstrated efficacy in the treatment of HIV-DSP. Data from two phase III, double-blind studies were integrated to further analyze the efficacy and safety of NGX-4010 and explore the effect of demographic and baseline factors on NGX-4010 treatment in HIV-DSP. Data from two similarly designed studies in which patients with HIV-DSP received NGX-4010 or a low-concentration control patch (capsaicin 0.04% w/w) for 30 or 60 minutes were integrated. Efficacy assessments included the mean percent change from baseline in Numeric Pain Rating Scale (NPRS) scores to Weeks 2–12. Safety and tolerability assessments included adverse events (AEs) and pain during and after treatment. Patients (n = 239) treated with NGX-4010 for 30 minutes demonstrated significantly (p = 0.0026) greater pain relief compared with controls (n = 100); the mean percent change in NPRS scores from baseline to Weeks 2–12 was −27.0% versus −15.7%, respectively. Patients who received a 60-minute application of NGX-4010 (n = 243) showed comparable pain reductions (−27.5%) to patients treated for 30 minutes, but this was not statistically superior to controls (n = 115). NGX-4010 was effective regardless of gender, baseline pain score, duration of HIV-DSP, or use of concomitant neuropathic pain medication, although NGX-4010 efficacy was greater in patients not receiving concomitant neuropathic pain medications. NGX-4010 was well tolerated; the most common AEs were application-site pain and erythema, and most AEs were mild to moderate. The transient increase in pain associated with NGX-4010 treatment decreased the day after treatment and returned to baseline by Day 2. A single 30-minute application of NGX-4010 provides significant pain relief for at least 12 weeks in patients with HIV-DSP and is well tolerated. Trial registration C107 = NCT00064623; C119 = NCT00321672
Full-text available
Chronic non-cancer-related pain affects a large proportion of the adult population and is often difficult to manage effectively. Although opioid analgesics have been used to relieve chronic pain of different etiologies, opioids are associated with a range of side effects that may reduce patient quality of life and lead to reduced compliance with treatment.Tapentadol is a centrally acting analgesic with 2 mechanisms of action, μ-opioid receptor agonism and norepinephrine reuptake inhibition, that is available in an extended-release formulation for the management of chronic pain. To review the efficacy of tapentadol extended release (ER) for the management of moderate to severe chronic nociceptive and neuropathic pain. Efficacy results are summarized for four 15-week phase 3 studies of tapentadol ER in patients with moderate to severe chronic osteoarthritis knee pain (2 studies; Identifiers: NCT00421928 and NCT00486811), low back pain (NCT00449176), and pain related to diabetic peripheral neuropathy (DPN; NCT00455520); a one-year phase 3 study of tapentadol ER in patients with moderate to severe chronic osteoarthritis pain or low back pain (NCT00361504); and a pooled analysis of data from the 15-week studies in patients with osteoarthritis knee pain or low back pain. A summary of the comparative tolerability for tapentadol ER and the active comparator used in these studies, oxycodone controlled release (CR), is provided. Results of these studies showed that tapentadol ER (100 - 250 mg bid) was effective for the management of moderate to severe chronic osteoarthritis knee pain, low back pain, and pain related to DPN. Tapentadol ER (100 - 250 mg bid) has been shown to provide comparable pain relief to oxycodone HCl CR (20 - 50 mg bid) for chronic osteoarthritis knee pain and low back pain over up to one year of treatment. Tapentadol ER (100 - 250 mg bid) was associated with an improved tolerability profile, particularly gastrointestinal tolerability profile, and with lower rates of treatment discontinuations and adverse event-related discontinuations compared with oxycodone HCl CR (50 - 250 mg bid) over up to one year of treatment in patients with osteoarthritis knee pain and low back pain. Differences in the design and duration of these phase 3 studies may limit comparisons of the efficacy results; nevertheless, this summary of efficacy results demonstrates the broad efficacy of tapentadol ER for different types of nociceptive and neuropathic pain. Tapentadol ER (100 - 250 mg bid) is effective for moderate to severe osteoarthritis pain, low back pain, and pain related to DPN and provides efficacy similar to that of oxycodone HCl CR (20 - 50 mg bid) for patients with osteoarthritis and low back pain. Tapentadol ER treatment has been associated with better gastrointestinal tolerability and compliance with therapy than oxycodone CR, which suggests that tapentadol ER may be a better option for the long-term management of chronic pain.
Full-text available
Capsaicin has long been used as a traditional medicine to treat pain and, recently, its mechanism of analgesic action has been discovered. This review article documents the clinical development of capsaicin to demonstrate that pharmacognosy still has a profound influence on modern-day drug development programs. Capsaicin is a highly selective agonist for the transient receptor potential channel vanilloid-receptor type 1 (TRPV1), which is expressed on central and peripheral terminals of nociceptive primary sensory neurons. Knockout studies have revealed the importance of TRPV1 as a molecular pain integrator and target for novel analgesic agents. Topical application of capsaicin at the peripheral terminal of TRPV1-expressing neurons superficially denervates the epidermis in humans in a highly selective manner and results in hypoalgesia. In three recent randomized controlled trials, a patch containing high-concentration capsaicin demonstrated meaningful efficacy and tolerability relative to a low-concentration capsaicin control patch in patients with peripheral neuropathic pain. Data from clinical practice will determine if the high-concentration capsaicin patch is effective in real-world settings.
Full-text available
Topical capsaicin formulations are used for pain management. Safety and modest efficacy of low-concentration capsaicin formulations, which require repeated daily self-administration, are supported by meta-analyses of numerous studies. A high-concentration capsaicin 8% patch (Qutenza™) was recently approved in the EU and USA. A single 60-min application in patients with neuropathic pain produced effective pain relief for up to 12 weeks. Advantages of the high-concentration capsaicin patch include longer duration of effect, patient compliance, and low risk for systemic effects or drug-drug interactions. The mechanism of action of topical capsaicin has been ascribed to depletion of substance P. However, experimental and clinical studies show that depletion of substance P from nociceptors is only a correlate of capsaicin treatment and has little, if any, causative role in pain relief. Rather, topical capsaicin acts in the skin to attenuate cutaneous hypersensitivity and reduce pain by a process best described as 'defunctionalization' of nociceptor fibres. Defunctionalization is due to a number of effects that include temporary loss of membrane potential, inability to transport neurotrophic factors leading to altered phenotype, and reversible retraction of epidermal and dermal nerve fibre terminals. Peripheral neuropathic hypersensitivity is mediated by diverse mechanisms, including altered expression of the capsaicin receptor TRPV1 or other key ion channels in affected or intact adjacent peripheral nociceptive nerve fibres, aberrant re-innervation, and collateral sprouting, all of which are defunctionalized by topical capsaicin. Evidence suggests that the utility of topical capsaicin may extend beyond painful peripheral neuropathies.
The Neuropathic Pain Special Interest Group of the International Association for the Study of Pain recently sponsored the development of evidence-based guidelines for the pharmacological treatment of neuropathic pain. Tricyclic antidepressants, dual reuptake inhibitors of serotonin and norepinephrine, calcium channel alpha(2)-delta ligands (ie, gabapentin and pregabalin), and topical lidocaine were recommended as first-line treatment options on the basis of the results of randomized clinical trials. Opioid analgesics and tramadol were recommended as second-line treatments that can be considered for first-line use in certain clinical circumstances. Results of several recent clinical trials have become available since the development of these guidelines. These studies have examined botulinum toxin, high-concentration capsaicin patch, lacosamide, selective serotonin reuptake inhibitors, and combination therapies in various neuropathic pain conditions. The increasing number of negative clinical trials of pharmacological treatments for neuropathic pain and ambiguities in the interpretation of these negative trials must also be considered in developing treatment guidelines. The objectives of the current article are to review the Neuropathic Pain Special Interest Group guidelines for the pharmacological management of neuropathic pain and to provide a brief overview of these recent studies.
Neuropathic pain is a disease of global burden. Its symptoms include spontaneous and stimulus-evoked painful sensations. Several maladaptive mechanisms underlying these symptoms have been elucidated in recent years: peripheral sensitization of nociception, abnormal excitability of afferent neurons, central sensitization comprising pronociceptive facilitation, disinhibition of nociception and central reorganization processes, and sympathetically maintained pain. This review aims to illustrate these pathophysiological principles, focussing on molecular and neurophysiological findings. Finally therapeutic options based on these findings are discussed.
In the majority of patients, existing therapies for neuropathic pain are far from effective. Furthermore, all current treatments are symptomatic rather than disease-modifying or curative. A range of therapeutic modalities is emerging, targeting a variety of mechanisms, but choosing the best target and evaluating the resulting therapies against the many types of neuropathic pain disorders is not an easy task. In this article, we suggest a shift in emphasis of the drug discovery paradigm toward unbiased evaluation of the particular neurobiological mechanisms contributing to neuropathic pain in individual patients. Genomewide association studies and other discovery science approaches to identify significant novel targets should be given priority as should the development of increasingly sophisticated tools for measuring and categorizing neuropathic pain.
This second European Federation of Neurological Societies Task Force aimed at updating the existing evidence about the pharmacological treatment of neuropathic pain since 2005. Studies were identified using the Cochrane Database and Medline. Trials were classified according to the aetiological condition. All class I and II randomized controlled trials (RCTs) were assessed; lower class studies were considered only in conditions that had no top-level studies. Treatments administered using repeated or single administrations were considered, provided they are feasible in an outpatient setting. Most large RCTs included patients with diabetic polyneuropathies and post-herpetic neuralgia, while an increasing number of smaller studies explored other conditions. Drugs generally have similar efficacy in various conditions, except in trigeminal neuralgia, chronic radiculopathy and HIV neuropathy, with level A evidence in support of tricyclic antidepressants (TCA), pregabalin, gabapentin, tramadol and opioids (in various conditions), duloxetine, venlafaxine, topical lidocaine and capsaicin patches (in restricted conditions). Combination therapy appears useful for TCA-gabapentin and gabapentin-opioids (level A). There are still too few large-scale comparative studies. For future trials, we recommend to assess comorbidities, quality of life, symptoms and signs with standardized tools and attempt to better define responder profiles to specific drug treatments.